Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden

Acta Paediatrica, International Journal of Paediatrics

Volumn 100, Issue 10, 2011, Pages 1306-1314

  Neovius, Kristian ^a   Buesch, Katharina ^b   Sandström, Kristina ^c   Neovius, Martin ^a,d  

^a Snowbox Research AB   (Sweden)

^b ABBOTT GMBH AND CO KG   (Germany)

^c Abbott Scandinavia AB   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cost effectiveness; Economic evaluation; Palivizumab; Preterm infants; Respiratory syncytial virus prophylaxis

Indexed keywords

PALIVIZUMAB;

ARTICLE; ASTHMA; BOVINE RESPIRATORY SYNCYTIAL VIRUS INFECTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; INFANT MORTALITY; MAJOR CLINICAL STUDY; NEWBORN; PREMATURITY; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SWEDEN;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MARKOV CHAINS; MODELS, BIOLOGICAL; QUALITY-ADJUSTED LIFE YEARS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SWEDEN;

EID: 80052827424     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2011.02309.x     Document Type: Article

References (28)

1. Simoes EA,. Respiratory syncytial virus infection. Lancet 1999; 354: 847-52. (Pubitemid 29415599)
2. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ,. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282: 1440-6. (Pubitemid 29493797)
3. Naver L, Eriksson M, Ewald U, Linde A, Lindroth M, Schollin J,. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden. Acta Paediatr 2004; 93: 1470-3. (Pubitemid 39457061)
4. Eriksson M, Bennet R, Rotzen-Ostlund M, von Sydow M, Wirgart BZ,. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr 2002; 91: 593-8. (Pubitemid 34620649)
5. Terletskaia-Ladwig E, Enders G, Schalasta G, Enders M,. Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological study. BMC Infect Dis 2005; 5: 20.
6. IMpact Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102: 531-7.
7. Stensballe LG, Kristensen K, Simoes EA, Jensen H, Nielsen J, Benn CS, et al., Atopic disposition, wheezing, and subsequent respiratory syncytial virus hospitalization in Danish children younger than 18 months: a nested case-control study. Pediatrics 2006; 118: e1360-8. (Pubitemid 46393640)
8. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A,. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008; 12: iii, ix-x, 1-86.
9. Sampalis JS,. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003; 143: S150-6. (Pubitemid 37456913)
10. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B,. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000; 161: 1501-7. (Pubitemid 30329018)
11. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Bjorksten B,. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995; 95: 500-5.
12. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al., Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005; 171: 137-41. (Pubitemid 40105412)
13. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al., Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010; 65: 1045-52.
14. Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, et al., Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004; 89: 673-8.
15. Chiou CF, Weaver MR, Bell MA, Lee TA, Krieger JW,. Development of the multi-attribute Pediatric Asthma Health Outcome Measure (PAHOM). Int J Qual Health Care 2005; 17: 23-30. (Pubitemid 40260140)
16. Socialstyrelsen. National Board of Health and Welfare [ (accessed on August 20, 2010)].
17. Brouwer WB, Niessen LW, Postma MJ, Rutten FF,. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005; 331: 446-8. (Pubitemid 41176388)
18. WHO. Immunization, Vaccines and Biologicals. WHO Guide for standardisation of economic evaluations of immunization programmes [ (accessed on August 10, 2010)].
19. Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW,. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006; 160: 1070-6. (Pubitemid 44520638)
20. Nuijten M, Lebmeier M, Wittenberg W,. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. Pharmacoeconomics 2007; 25: 55-71. (Pubitemid 46072368)
21. Nuijten MJ, Wittenberg W, Lebmeier M,. Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis. Pharmacoeconomics 2007; 25: 55-71. (Pubitemid 46072368)
22. Resch B, Gusenleitner W, Nuijten MJ, Lebmeier M, Wittenberg W,. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008; 30: 749-60. (Pubitemid 351680486)
23. Yount LE, Mahle WT,. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004; 114: 1606-11. (Pubitemid 41754926)
24. Chirico G, Ravasio R, Sbarigia U,. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr 2009; 35: 4.
25. Karolinska Universitetssjukhus Utomlänsprislista. Karolinska University Hospital Outside County Price List. Stockholm: Karolinska Universitetssjukhus Utomlänsprislista, 2009.
26. Arnlind MH, Nokela M, Rehnberg C, Jonsson EW,. The relationship between pharmaceutical costs, disease severity, and health-related quality of life in asthmatics in Swedish primary care. J Asthma 2006; 43: 585-91. (Pubitemid 44581252)
27. Hederos CA, Janson S, Hedlin G,. Six-year follow-up of an intervention to improve the management of preschool children with asthma. Acta Paediatr 2009; 98: 1939-44.
28. Weiss KB, Sullivan SD, Lyttle CS,. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol 2000; 106: 493-9. (Pubitemid 32037702)